Stock Ticker

  • Loading stock data...

Biostage Inc (NASDAQ:BSTG) Unveils Positive Preclinical Data Of Cellspan™ Esophageal Implant As It Looks Forward To Generate More Revenues

The International Society for Stem Cell Research (ISSCR) 2017 Annual Meeting that was held on June 14-17, 2017 in Boston, MA was to determine a lot in the future of the medical world. One of the companies that made presentations was Biostage Inc (NASDAQ:BSTG). Today, the company has got some great news for all the concerned parties. It has announced that it successfully presented positive preclinical data of its proprietary Cellspan™ Esophageal Implant, and that is a great promise for patients around the globe.

While recently addressing a press conference, one of the top officials working with the provider said that they were excited that they had been sailing smoothly in business. That is since they started developing bioengineered organ implants to treat cancers and other life-threatening conditions of the esophagus, trachea and bronchus. Biostage’s Senior Research Associate, KaLia Burnette on Friday, June 16, 2017 presented the poster (No. F-3043) and on it was the title, “Esophageal Regeneration with a Cell-Seeded Tissue Engineered Graft.”

Biostage’s President and Chief Medical officer, Saverio La Francesca while recently speaking to a number of top journalists said, “Current reconstruction approaches are limited to utilization of an autologous conduit such as the stomach, small bowel, or colon, and we believe that our Cellspan Esophageal Implant, which provides the potential for esophageal replacement or regeneration for circumferential, full thickness defects, would have significant clinical application and provide a groundbreaking solution for this unmet medical need.”

According to, this company’s engineered esophageal replacement serves the various patients worldwide with new therapeutic options in difficult reconstructive circumstances. It is a major development since it is taking away the great need to carry out tissue transfers as well as some other extensive operations.

The CEO of Biostage, Jim McGorry, in a recent board meeting outlined that the provider’s ongoing large-animal model preclinical studies by utilizing its proprietary Cellframe™ technology will be able to continually and consistently demonstrate that esophageal regeneration is feasible and reproducible with the human Cellspan Esophageal Implant. Biostage Inc is looking forward to transition its technology into the first-in-human clinical study by the end of 2017.

Published by Van Bettauer

Van Bettauer is a financial aficionado from Vancouver, British Columbia. He currently studies at UBC, pursuing a Bachelors of Science degree. Van has been freelance writing for many years, specializing in copywriting, report writing and article writing. The combination of his scientific studies and writing experience brings a new and fresh perspective to the financial world. Visit Bettauer's Google+ page at the following address:

Recent Stories

Sponsored Content

Sign Up To Get Our Latest Stocks Alerts